All Videos

A panelist discusses how selecting the optimal laser device requires careful consideration of wavelength, pulse duration, and spot size to effectively target specific skin concerns while minimizing potential adverse effects.

Melodie Young, MSN, A/GNP-C, discusses how clinical and practical considerations, such as disease severity, patient preferences, and comorbidities, should guide the selection of treatment for prurigo nodularis, and emphasizes the importance of educating patients about the role of systemic therapies, addressing their concerns, and improving awareness of available treatment options.

Melodie Young, MSN, A/GNP-C, discusses how the FDA-approved systemic treatments for prurigo nodularis, dupilumab and nevolizumabnemolizumab, differ in their mechanisms of action—dupilumab targeting IL-4 and IL-13, and nevolizumabnemolizumab targeting IL-31—and highlights their similar efficacy in reducing pruritus and lesion size, while also considering differences in safety profiles and treatment considerations.

Melodie Young, MSN, A/GNP-C, discusses how to effectively communicate with patients about managing itch in prurigo nodularis, offering practical tips such as setting realistic expectations, emphasizing the importance of consistent skin care routines, and exploring both pharmacologic and non-pharmacologic strategies to alleviate discomfort.

Melodie Young, MSN, A/GNP-C, discusses how diagnosing prurigo nodularis can be challenging due to its similarity to other pruritic conditions, and highlights the importance of recognizing key features and patient subtypes with increased prevalence to accurately differentiate it from conditions like eczema and psoriasis.

Panelists discuss how the efficacy data from the Effisayil 2 trial demonstrate that spesolimab significantly delayed the time to first GPP flare and reduced flare severity, highlighting its potential as an effective treatment for preventing life-threatening flares in GPP patients.

Panelists discuss how factors such as tumor size, location, patient age, and overall health guide the decision between surgical excision and nonsurgical treatments such as topical therapies or radiation for managing basal cell carcinoma (BCC) effectively.

Panelists discuss how the Effisayil 2 trial included diverse patient demographics across different spesolimab dose groups, with baseline characteristics such as age, disease severity, and history of GPP flares influencing the treatment outcomes and safety data.

Melodie Young, MSN, A/GNP-C, discusses how prurigo nodularis imposes a significant physical and mental burden on patients, with chronic itching, skin lesions, and emotional distress leading to a reduced quality of life and increased anxiety and depression.

Karan Lal, DO, MS, FAAD, discusses how to balance safety and efficacy considerations while promoting treatment adherence in young vitiligo patients, focusing on the unique challenges and monitoring requirements for this vulnerable population.

Karan Lal, DO, MS, FAAD, discusses how to optimize vitiligo management in pediatric patients through personalized treatment selection and age-appropriate counseling strategies that address both the physical and psychosocial aspects of the condition.

Karan Lal, DO, MS, FAAD, discusses how treatment approaches for vitiligo differ between adult and pediatric populations, with experts examining distinct patterns of care, therapeutic considerations, and clinical pearls specific to each age group.

Panelists discuss how managing atopic dermatitis presents complex clinical challenges, including treatment resistance, medication adherence, identifying triggers, and tailoring therapies to individual patient needs and disease severity.

Panelists discuss how patients with atopic dermatitis face numerous obstacles to optimal care, including limited access to specialists, high treatment costs, inadequate insurance coverage, and the need for more effective long-term management options.

Panelists discuss how atopic dermatitis presents and requires different management approaches across age groups, with distinct challenges in diagnosis, treatment adherence, and quality of life impacts between pediatric and adult populations.

Panelists discuss how a collaborative approach involving dermatologists, oncologists, and surgeons can optimize treatment outcomes and quality of life for patients with basal cell carcinoma through personalized, comprehensive care plans.

Panelists discuss how the primary endpoint of the Effisayil 2 trial focused on the time to first GPP flare, while secondary endpoints assessed flare severity, quality of life, and inflammatory markers, providing a comprehensive evaluation of spesolimab's impact on GPP management.

James Song, MD, discusses how clinical trial data demonstrates the risk-benefit profile of vitiligo therapies, with particular focus on balancing potential adverse effects of Janus kinase inhibitors against their proven efficacy in achieving repigmentation.

James Song, MD, discusses how Janus kinase (JAK) inhibitors represent a breakthrough in vitiligo treatment by effectively targeting the immune pathways responsible for depigmentation, offering patients a powerful new therapeutic option with promising repigmentation results.

James Song, MD, discusses how recent advances in vitiligo treatment, including Janus kinase inhibitors and targeted immunotherapies, are transforming the therapeutic landscape with more effective options for repigmentation and disease management.

Panelists discuss how identifying optimal timing for treatment switches and emerging therapeutic innovations are reshaping the management landscape for hidradenitis suppurativa, with the potential to improve long-term patient outcomes.

Panelists discuss how managing patient expectations while implementing combination treatment approaches can optimize outcomes in hidradenitis suppurativa, emphasizing the importance of clear communication about treatment goals and timelines.